Introducing REYOBIQ™

by | Mar 20, 2025 | GBM, LM, PBC, Uncategorized

Introducing REYOBIQ™: The FDA-Accepted Proprietary Name for Plus Therapeutics’ Lead Drug Candidate Big News from Plus Therapeutics! The U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name REYOBIQ™ (rhenium Re186 obisbemeda) for our...

Nature Publication

by | Mar 7, 2025 | GBM

Phase 1 Clinical Trial Results for Rhenium (186Re) Obisbemeda in Recurrent Glioblastoma (GBM) Now in Nature Communications 📢 Exciting News! The results of our Phase 1 clinical trial for Rhenium (186Re) Obisbemeda in recurrent glioblastoma (GBM) have been published in...

Advancing Treatment for Recurrent Glioblastoma

by | Mar 2, 2025 | GBM

ReSPECT-GBM Clinical Trial: Advancing Treatment for Recurrent Glioblastoma (GBM) Glioblastoma (GBM) is one of the most aggressive and treatment-resistant brain cancers, with limited therapeutic options available for patients with recurrent disease. The ReSPECT-GBM...

#RareDiseaseDay2025

by | Feb 28, 2025 | GBM, LM, PBC, Uncategorized

Shining a Light on Rare Diseases: Raising Awareness Together At Plus Therapeutics, we are committed to advancing research and innovative treatments for rare and challenging diseases. Today, on Rare Disease Day, we stand with patients, caregivers, and advocates...

Welcome Michael Rosol, PhD!

by | Feb 20, 2025 | GBM, LM, PBC, Uncategorized

Plus Therapeutics Appoints Michael Rosol, Ph.D., as Chief Development Officer We are excited to announce the appointment of Michael Rosol, Ph.D., as Chief Development Officer at Plus Therapeutics. In this role, Dr. Rosol will oversee the company’s clinical,...